The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

A higher intake of riboflavin was associated with a reduced risk of developing psoriasis, but no other single vitamin associations were observed.

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

But if a particularly persistent and unsightly toenail fungus is giving you some trepidation, here is one powerful $19 ...

Using social media as a pharma brand can feel risky due to regulatory constraints - but it can make a big impact when used in ...

It can take up to a year for toenail fungus to completely resolve with treatment, and it can come back without proper ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Arcutis Biotherapeutics has published 14 consensus statements developed by the Genital Psoriasis Wellness Consortium ... commercial drug insurance or whose prescription claims are eligible ...